The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genetic polymorphisms to predict progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone therapy: Results from the NCI 9012 trial.
 
Costantine Albany
Honoraria - Sanofi
Speakers' Bureau - Sanofi
Research Funding - Astex Pharmaceuticals (Inst)
 
Stephanie Daignault-Newton
Consulting or Advisory Role - Augmenix
Research Funding - Bayer
 
Todd C Skaar
No Relationships to Disclose
 
Joseph Ipe
No Relationships to Disclose
 
Javed Siddiqui
No Relationships to Disclose
 
Przemyslaw Twardowski
No Relationships to Disclose
 
Mark N. Stein
Research Funding - Abbvie (Inst); Advaxis (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Janssen Oncology (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Oncoceutics (Inst)
 
Lakshmi Priya Kunju
No Relationships to Disclose
 
Arul M. Chinnaiyan
No Relationships to Disclose
 
Robert B. Montgomery
Research Funding - ESSA; Janssen Oncology; Medivation/Astellas; Tokai Pharmaceuticals
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Consulting or Advisory Role - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Daniel H. Shevrin
No Relationships to Disclose
 
Young E. Whang
Research Funding - Astellas Pharma (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Tokai Pharmaceuticals (Inst)
 
Megan Veresh Caram
No Relationships to Disclose
 
David C. Smith
Research Funding - Agensys (Inst); Aragon Pharmaceuticals (Inst); Atterocor (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); Eisai (Inst); Exelixis (Inst); ImClone Systems (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Millennium (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); PSMA Development Company (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Seagen (Inst); Tekmira (Inst); Teva (Inst)
 
Felix Yi-Chung Feng
Leadership - PFS Genomics
Stock and Other Ownership Interests - PFS Genomics
Consulting or Advisory Role - Celgene; GenomeDx; Medivation/Astellas
Research Funding - Celgene; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst)
 
Walter Michael Stadler
Honoraria - AstraZeneca; Bayer; CVS Caremark; Johnson & Johnson; Merck; Sotio
Consulting or Advisory Role - AstraZeneca; Bayer; CVS Caremark; Johnson & Johnson; Merck; Sotio
Research Funding - Active Biotech (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Johnson & Johnson (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst)
Other Relationship - American Cancer Society; UpToDate
 
Maha Hussain
Consulting or Advisory Role - AstraZeneca; Essa; Johnson & Johnson; Synthon
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Genentech (Inst); Medivation (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753